April 22, 2015
Increased overall survival and a longer time before tumor recurrence is associated with low presurgery uptake of a labeled glucose analogue, a marker of metabolic activity, in the primary tumor of patients with stage I non-small cell lung cancer (NSCLC). Patients with high uptake of labeled glucose may benefit from additional therapy following surgery.
Surgery is the standard of care for patients with stage I NSCLC but not all patients are cured, as demonstrated by a 5-year survival rate of less than 60% in these patients. There is a clear need for a diagnostic test to identify which patients should receive postsurgical therapy, such as chemotherapy, and which patients do not need further treatment, thus avoiding unnecessary treatment-related toxicity and complications.
Fluorodeoxyglucose (FDG) is radiolabeled analogue of glucose whose concentration within a tumor can be measured with a positron emission tomography (PET) imaging scanner.